Kontron finds a buyer

Article

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity

U.K. ultrasound and patient monitoring firm Kontron Instruments found a buyer last month, only weeks after going into receivership. The company was purchased Feb. 5 by Innermail Ltd., a subsidiary of Charterhouse Group International, a private equity company based in New York City.

At the time it went into receivership, Kontron owed roughly $8 million to its creditors. Its assets were intellectual property rights to its monitoring products, an electronic assembly plant, raw materials, and stock, according to Kontron's receiver, KPMG, an international accounting firm also based in the U.K. (SCAN 2/17/99). Ninety Kontron employees lost jobs as a result of the company's failure, although KPMG anticipates that several of these employees will be hired by Innermail. Charterhouse Group was unavailable for comment on the Kontron purchase.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.